These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 8882925)

  • 1. Health insurance: coverage of autologous bone marrow transplantation for breast cancer.
    Jaggar SF
    Oncology (Williston Park); 1996 Sep; 10(9):1329-32, 1337-8, 1340 passim. PubMed ID: 8882925
    [No Abstract]   [Full Text] [Related]  

  • 2. Perspectives. Indefinite results in ABMT (autologous bone marrow transplantation) trials add to challenges for practice standards, quality assurance in cancer care.
    Cunningham R
    Med Health; 1999 Apr; 53(16):suppl 1-4. PubMed ID: 10387749
    [No Abstract]   [Full Text] [Related]  

  • 3. ABMT and breast cancer.
    Firshein J
    Healthplan; 1999; 40(4):30-3, 35-7. PubMed ID: 10557735
    [No Abstract]   [Full Text] [Related]  

  • 4. Health insurance coverage for emerging medical technologies: a new approach.
    Puzio D
    Tort Trial Insur Pract Law J; 2003; 38(4):1019-47. PubMed ID: 14503539
    [No Abstract]   [Full Text] [Related]  

  • 5. Evaluating promising new treatments for life-threatening disease: implications of the HDC/ABMT experience for treating breast cancer.
    Edwards S
    Find Brief; 2005 Jan; 8(1):1-3. PubMed ID: 15672527
    [No Abstract]   [Full Text] [Related]  

  • 6. Cancer coverage. Why are insurers paying for this "experimental" therapy?
    Med Econ; 1996 Sep; 73(17):38. PubMed ID: 10161873
    [No Abstract]   [Full Text] [Related]  

  • 7. Experimental medical treatments: who should decide coverage?
    Collins JC
    Spec Law Dig Health Care Law; 1998 Jan; (226):9-45. PubMed ID: 10176412
    [No Abstract]   [Full Text] [Related]  

  • 8. Experimental medical treatments: who should decide coverage?
    Collins JC
    Seattle Univ Law Rev; 1997; 20(2):451-87. PubMed ID: 16528856
    [No Abstract]   [Full Text] [Related]  

  • 9. Variations in insurance coverage for autologous bone marrow transplantation for breast cancer.
    Krause KJ
    N Engl J Med; 1994 Aug; 331(5):329; author reply 330-1. PubMed ID: 8068113
    [No Abstract]   [Full Text] [Related]  

  • 10. Experimental treatment: can you do the right thing without going broke?
    Holoweiko M
    Bus Health; 1995 May; 13(5):38-40, 45-6, 48. PubMed ID: 10164496
    [No Abstract]   [Full Text] [Related]  

  • 11. Litigating the science of breast cancer treatment.
    Jacobson PD; Rettig RA; Aubry WM
    J Health Polit Policy Law; 2007 Oct; 32(5):785-818. PubMed ID: 17855717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Variation in approval by insurance companies of coverage for autologous bone marrow transplantation for breast cancer.
    Peters WP; Rogers MC
    N Engl J Med; 1994 Feb; 330(7):473-7. PubMed ID: 8289855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigational treatments: coverage, controversy, and consensus.
    Ader M
    Ann Health Law; 1996; (5):45-60. PubMed ID: 10164521
    [No Abstract]   [Full Text] [Related]  

  • 14. Variations in insurance coverage for autologous bone marrow transplantation for breast cancer.
    Cutler CM; Udvarhelyi IS; Winkenwerder W
    N Engl J Med; 1994 Aug; 331(5):329-30. PubMed ID: 8022449
    [No Abstract]   [Full Text] [Related]  

  • 15. The controversy over high-dose chemotherapy with autologous bone marrow transplant for breast cancer.
    Mello MM; Brennan TA
    Health Aff (Millwood); 2001; 20(5):101-17. PubMed ID: 11558695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autologous bone marrow transplants.
    Rose LJ
    Health Aff (Millwood); 2002; 21(2):308. PubMed ID: 11900184
    [No Abstract]   [Full Text] [Related]  

  • 17. The soul of an HMO.
    Larson E
    Time; 1996 Jan; 147(4):44-52. PubMed ID: 10153782
    [No Abstract]   [Full Text] [Related]  

  • 18. When an insurer calls your treatment experimental.
    Holoweiko M
    Med Econ; 1995 Sep; 72(17):171-2, 175-6, 178-82. PubMed ID: 10151340
    [No Abstract]   [Full Text] [Related]  

  • 19. ABMT and breast cancer: what have we learned?
    Brown E
    Physician Exec; 1999; 25(4):86-8. PubMed ID: 10557495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Defining experimental therapy--a third-party payer's dilemma.
    Newcomer LN
    N Engl J Med; 1990 Dec; 323(24):1702-4. PubMed ID: 2233969
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.